LSP
also invests · investor profileAcquired3 known investors
EQT Life Sciences (formerly LSP) is one of Europe's largest life sciences investment firms that invests in innovative companies developing therapeutics, medical devices, diagnostics, and healthtech solutions. The firm targets companies with the potential to address unmet clinical needs and improve patient outcomes, with a 30-year track record and approximately 3.5 billion euros raised across multiple funds.
Also known as EQT Life Sciences · Life Sciences Partners · LSP
Investors · 3
Company profile
researched Aug 2026LSP (Life Sciences Partners), rebranded EQT Life Sciences after its 2022 integration into EQT, is a European investment firm financing life sciences and healthcare companies. It invests in companies developing therapeutics, medical devices, diagnostics and healthtech globally, with typical investments of EUR 10-60 million per company. The firm operates three investment strategies: Life Sciences Funds (LSP 1-7), which are biotech funds covering drug development at all stages; Health Economic Funds, focused on later-stage medtech, digital health and diagnostics intended to improve care quality and reduce healthcare costs; and a Dementia Fund covering drug development and medical technology for neurodegenerative diseases.
The investment team is composed of professionals with medical, scientific, business and finance backgrounds, and the firm states it provides strategic, clinical, operational, financial and commercial support alongside capital. Its own materials cite a track record of about 30 years, roughly EUR 3.5 billion raised across 12 private funds, more than 150 private companies backed historically, and 65+ current portfolio companies supported by 30+ investment advisory professionals. Signature investments cited include argenx, Crucell and Neuravi; featured portfolio names include Amolyt Pharma, New Amsterdam Pharma, Onera Health and PanTera. The firm is also a founder and board member of the Oncode Institute and organizes the BioCapital Europe conference, whose 25th edition was held in March 2026.
Business model
The firm raises and manages/advises closed-end private funds on behalf of institutional and corporate limited partners, including pharmaceutical companies, and deploys that capital as equity investments in private life sciences companies, generating returns through exits. Since 2022 it operates as EQT Life Sciences, a business line within EQT's Private Capital segment.
Fund management/advisory economics on committed capital across its private funds, plus returns from equity investments realized at exit.
Traction
Company materials report about EUR 3.5 billion raised across 12 funds, 65+ portfolio companies, over 150 private companies backed since inception, and an investment range of EUR 10-60 million. LSP 7 closed at over EUR 1 billion in February 2022 and was described as the largest life sciences venture capital fund raised in Europe to date; it is backed in part by five pharmaceutical companies (four Asian, one US) and was expected to be deployed across 15-20 companies. Reported exits include Amolyt Pharma (entered 2019 from LSP 6, exited 2024).
Latest developments
Following the EQT acquisition completed in February 2022, the firm operates as EQT Life Sciences. In March 2026 it hosted the 25th edition of BioCapital Europe and published a retrospective on its evolution from LSP.
▸Full profile — market position, go-to-market, geography, history
Market position
Positions itself as one of Europe's largest and most experienced life sciences investors; its LSP 7 fund was reported as the largest European life sciences venture capital fund raised to date at its February 2022 close.
Emphasizes an investment team drawn from medicine, science, business and finance, three distinct strategies each with a dedicated team and scope, and hands-on strategic, clinical, operational, financial and commercial support to portfolio companies; since 2022 it also draws on EQT's fundraising platform, healthcare sector teams and in-house digitalization and sustainability expertise.
Go-to-market
The firm sources opportunities through its sector network and invites entrepreneurs to submit investment opportunities directly via its website, and maintains visibility through industry roles, publications and the BioCapital Europe conference.
On the investment side, privately held life sciences and healthcare companies in Europe and globally, including biotech drug developers at all stages, medtech, digital health and diagnostics companies; on the capital side, institutional fund investors and pharmaceutical corporate investors.
Geography
Headquartered in the Netherlands (Amsterdam), with additional offices in Munich and Boston as LSP; investments made in European and global companies, with portfolio companies including businesses in France.
History
LSP built a track record of investing in life sciences companies over roughly 30 years, raising more than EUR 3.0-3.1 billion (about USD 3.5-3.6 billion) and supporting over 150 companies, with offices in Amsterdam, Munich and Boston. In November 2021 LSP announced EUR 850 million raised for its flagship LSP 7 fund and a definitive agreement to be acquired by EQT AB, signed 10 November 2021. The final close of LSP 7 at over EUR 1 billion was announced on 11 February 2022, and the EQT transaction completed on 28 February 2022, after which LSP was renamed EQT Life Sciences and managing partner René Kuijten became Partner and Head of the new business line. In March 2026 the firm marked the 25th edition of BioCapital Europe and 25 years of activity under the EQT Life Sciences banner.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 7
launches, deals, and filingsThe firm marked the 25th edition of the BioCapital Europe conference and 25 years of EQT Life Sciences, publishing a retrospective on its evolution from LSP.
Following the closing of the EQT transaction, LSP was renamed EQT Life Sciences and formed a new business line within EQT's Private Capital business segment.
The acquisition of LSP by EQT AB was completed on 28 February 2022 (announced 1 March 2022) for total consideration of EUR 475 million, including a EUR 25 million earn-out; EQT issued 7,548,384 shares to LSP's selling shareholders, about 0.8 percent dilution. René Kuijten, previously Managing Partner at LSP, was appointed Partner and Head of EQT Life Sciences.
At completion of the EQT transaction, LSP Managing Partner René Kuijten was appointed Partner and Head of EQT Life Sciences.
LSP announced the final close of LSP 7 at over EUR 1 billion (hard cap), described as the largest life sciences venture capital fund raised in Europe to date. A single large investor added EUR 150 million after the EQT partnership announcement. The fund is backed in part by five pharmaceutical companies and is expected to be invested in 15-20 companies; four investments were already completed (Evommune, Egle Therapeutics, Hotspot and an undisclosed radiotherapy company).
EQT AB announced on 10 November 2021 that it had signed a definitive agreement to acquire LSP.
In November 2021 LSP announced it had raised EUR 850 million for its flagship LSP 7 fund and its intention to join forces with EQT.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- LSPlspvc.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does LSP do?
- European life sciences investment firm, now EQT Life Sciences, backing therapeutics, medical device, diagnostics and healthtech companies.
- Who are LSP's investors?
- LSP's investors include KfW Capital, Tesi (Finnish Industry Investment Ltd), EIF.